Meril Debuts India’s First Homegrown TEER MedTech for Mitral Valve Repair

The device is specifically intended for patients with severe MR who face elevated surgical risks due to conditions like hypertension, diabetes, obesity, advanced age, physical frailty, or other health complications.

Meril Life Sciences has introduced MyClip, India’s first Transcatheter Edge-To-Edge Repair (TEER) system for treating severe mitral regurgitation (MR).

With this launch, Meril has become the first Indian company to offer both transcatheter valve replacement and repair platforms.

The MyClip system represents a significant addition to India’s growing structural heart solutions portfolio, addressing a critical cardiac care need for high-risk patients.

The device is specifically intended for patients with severe MR who face elevated surgical risks due to conditions like hypertension, diabetes, obesity, advanced age, physical frailty, or other health complications. Left untreated, severe MR carries a high mortality rate, with one-year deaths reported as high as 57%.

The MyClip TEER procedure is minimally invasive, typically completed within an hour, and allows patients to be discharged within 3–5 days. Most patients are able to resume light daily activities shortly after discharge.

Supporting the benefits of device-based therapy for MR, the COAPT study, published in the New England Journal of Medicine, found that such interventions significantly reduced hospitalizations and mortality rates compared to standard medical treatment.

In India, an estimated 150 TEER procedures are currently performed annually, with a noticeable number of patients falling within the 30–60 years age group, highlighting the need for early intervention.

Commenting on the launch, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, ''In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post-myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we’re witnessing early adoption. Meril’s efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country.''

Bhatt further added, “With MyClip, Meril is reshaping the country’s role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril’s nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation.''

Stay tuned for more such updates on Digital Health News